Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

At prespecified interim analysis of RCT (n=263, China), progression-free survival was significantly longer with this PD-1 inhibitor than with placebo (median 9.7 vs. 6.9 months; HR 0.54 [95% CI 0.39–0.76; p=0.0002). Serious adverse events were reported in 44% & 37%, respectively.

Source:

The Lancet Oncology